EMPLOYMENT AGREEMENTEmployment Agreement • September 23rd, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
This Executive Employment Agreement (the “Agreement”) is made and entered into effective as of September 23, 2024 (the “Effective Date”) by and between Acadia Pharmaceuticals Inc., a Delaware Corporation (the “Company”), and Catherine Owen Adams (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to each as a “Party”.
ACADIA PHARMACEUTICALS INC. EXECUTIVE TRANSITION AGREEMENTExecutive Transition Agreement • September 23rd, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Transition Agreement (“Transition Agreement”), replaces and supersedes the Amended and Restated Executive Employment Agreement dated September 1, 2015 (the “Employment Agreement”) and all other employment or employment-related agreements or commitments entered into prior to the Effective Date of this Transition Agreement (except as otherwise provided in this Transition Agreement), including the Management Severance Benefit Plan (the “Management Severance Plan”) and Participation Agreement thereunder dated February 5, 2016 (the “Participation Agreement” and, together with the Management Severance Plan, the “Severance Plan”) and the Amended and Restated Change in Control Severance Benefit Plan and Participation Agreement thereunder dated July 15, 2014 (collectively with the Severance Plan and the Employment Agreement, the “Prior Agreements”), by and among Acadia Pharmaceuticals Inc., a Delaware corporation, (the “Company”), and Stephen R. Davis (the “Executive”). This Tran
